Drug intelligence / Profile preview

bleomycin + cisplatin + etoposide + ifosfamide + methotrexate + vincristine

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

This is a multi-drug chemotherapy combination regimen used primarily for treating advanced testicular cancer and other germ cell tumors. The regimen combines several antineoplastic agents with different mechanisms of action to target cancer cells through multiple pathways. This intensive combination approach is typically used for patients with poor-prognosis features or advanced disease.

Targets

TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNADHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on bleomycin + cisplatin + etoposide + ifosfamide + methotrexate + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bleomycin + cisplatin + etoposide + ifosfamide + methotrexate + vincristine.

Explore the full profile